146 related articles for article (PubMed ID: 14609622)
21. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
Kloner RA
Circulation; 2004 Nov; 110(19):3149-55. PubMed ID: 15533876
[No Abstract] [Full Text] [Related]
22. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing.
Kloner RA; Jackson G; Hutter AM; Mittleman MA; Chan M; Warner MR; Costigan TM; Vail GM
Am J Cardiol; 2006 Jun; 97(12):1778-84. PubMed ID: 16765134
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction.
Padma-Nathan H
Am J Cardiol; 2003 Nov; 92(9A):19M-25M. PubMed ID: 14609620
[TBL] [Abstract][Full Text] [Related]
24. Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
Rosen RC; Kostis JB
Am J Cardiol; 2003 Nov; 92(9A):9M-18M. PubMed ID: 14609619
[TBL] [Abstract][Full Text] [Related]
25. The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease.
Patterson D; Kloner R; Effron M; Emmick J; Bedding A; Warner M; Mitchell M; Braat S; MacDonald T
Br J Clin Pharmacol; 2005 Nov; 60(5):459-68. PubMed ID: 16236035
[TBL] [Abstract][Full Text] [Related]
26. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial.
Maggiorini M; Brunner-La Rocca HP; Peth S; Fischler M; Böhm T; Bernheim A; Kiencke S; Bloch KE; Dehnert C; Naeije R; Lehmann T; Bärtsch P; Mairbäurl H
Ann Intern Med; 2006 Oct; 145(7):497-506. PubMed ID: 17015867
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.
Eardley I; Gentile V; Austoni E; Hackett G; Lembo D; Wang C; Beardsworth A
BJU Int; 2004 Oct; 94(6):871-7. PubMed ID: 15476525
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction.
Seftel AD; Wilson SK; Knapp PM; Shin J; Wang WC; Ahuja S
J Urol; 2004 Aug; 172(2):652-7. PubMed ID: 15247754
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
[TBL] [Abstract][Full Text] [Related]
30. Tadalafil.
Curran M; Keating G
Drugs; 2003; 63(20):2203-12; discussion 2213-4. PubMed ID: 14498756
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Kukreja RC
Br J Pharmacol; 2007 Mar; 150(5):538-40. PubMed ID: 17245364
[TBL] [Abstract][Full Text] [Related]
32. The cardiovascular safety of tadalafil.
Reffelmann T; Kieback A; Kloner RA
Expert Opin Drug Saf; 2008 Jan; 7(1):43-52. PubMed ID: 18171313
[TBL] [Abstract][Full Text] [Related]
33. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.
Gratzke C; Uckert S; Kedia G; Reich O; Schlenker B; Seitz M; Becker AJ; Stief CG
Urol Res; 2007 Feb; 35(1):49-54. PubMed ID: 17102958
[TBL] [Abstract][Full Text] [Related]
34. Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors.
Jackson G
Am J Cardiol; 2005 Dec; 96(12B):32M-36M. PubMed ID: 16387564
[TBL] [Abstract][Full Text] [Related]
35. Erectile dysfunction, sildenafil and cardiovascular risk.
Chew KK; Stuckey BG; Thompson PL
Med J Aust; 2000 Mar; 172(6):279-83. PubMed ID: 10860094
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular effects of phosphodiesterase 5 inhibitors.
Reffelmann T; Kloner RA
Curr Pharm Des; 2006; 12(27):3485-94. PubMed ID: 17017941
[TBL] [Abstract][Full Text] [Related]
37. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of tadalafil in clinical populations.
Lewis RW; Sadovsky R; Eardley I; O'Leary M; Seftel A; Wang WC; Shen W; Walker DJ; Wong DG; Ahuja S
J Sex Med; 2005 Jul; 2(4):517-31. PubMed ID: 16422847
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial.
Carrier S; Brock GB; Pommerville PJ; Shin J; Anglin G; Whitaker S; Beasley CM
J Sex Med; 2005 Sep; 2(5):685-98. PubMed ID: 16422827
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil.
McMahon C
J Sex Med; 2004 Nov; 1(3):292-300. PubMed ID: 16422959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
